tradingkey.logo
tradingkey.logo
検索

AN2 Therapeutics Inc

ANTX
ウォッチリストに追加
4.550USD
+0.110+2.48%
終値 11-13 16:00(ET)
171.72M時価総額
損失額直近12ヶ月PER

AN2 Therapeutics Incについて 企業名

AN2 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.

AN2 Therapeutics Inc プロフィール

企業コードANTX
会社名AN2 Therapeutics Inc
上場日Mar 25, 2022
最高経営責任者「CEO」Easom (Eric)
従業員数22
証券種類Ordinary Share
決算期末Mar 25
本社所在地1300 El Camino Real, Suite 100
都市MENLO PARK
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号94025
電話番号16503319090
ウェブサイトhttps://www.an2therapeutics.com/
企業コードANTX
上場日Mar 25, 2022
最高経営責任者「CEO」Easom (Eric)

AN2 Therapeutics Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Eric Easom
Mr. Eric Easom
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.36M
-8.27%
Mr. Joseph S. (Joe) Zakrzewski
Mr. Joseph S. (Joe) Zakrzewski
Independent Director
Independent Director
551.42K
--
Dr. Sanjay Chanda, Ph.D.
Dr. Sanjay Chanda, Ph.D.
Chief Development Officer
Chief Development Officer
103.54K
+36.70%
Dr. Gilbert Lynn Marks, M.D.
Dr. Gilbert Lynn Marks, M.D.
Independent Director
Independent Director
84.16K
+2.71%
Mr. Kabeer Aziz
Mr. Kabeer Aziz
Independent Director
Independent Director
61.57K
+4.00%
Mr. Joshua M. (Josh) Eizen, J.D.
Mr. Joshua M. (Josh) Eizen, J.D.
Chief Operating Officer, Chief Legal Officer, Corporate Secretary
Chief Operating Officer, Chief Legal Officer, Corporate Secretary
56.23K
-5.03%
Ms. Lucy O. Day
Ms. Lucy O. Day
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Lead Independent Director
Lead Independent Director
--
--
Dr. Rob Readnour, Ph.D.
Dr. Rob Readnour, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia (Patty) Martin
Ms. Patricia (Patty) Martin
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Eric Easom
Mr. Eric Easom
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.36M
-8.27%
Mr. Joseph S. (Joe) Zakrzewski
Mr. Joseph S. (Joe) Zakrzewski
Independent Director
Independent Director
551.42K
--
Dr. Sanjay Chanda, Ph.D.
Dr. Sanjay Chanda, Ph.D.
Chief Development Officer
Chief Development Officer
103.54K
+36.70%
Dr. Gilbert Lynn Marks, M.D.
Dr. Gilbert Lynn Marks, M.D.
Independent Director
Independent Director
84.16K
+2.71%
Mr. Kabeer Aziz
Mr. Kabeer Aziz
Independent Director
Independent Director
61.57K
+4.00%
Mr. Joshua M. (Josh) Eizen, J.D.
Mr. Joshua M. (Josh) Eizen, J.D.
Chief Operating Officer, Chief Legal Officer, Corporate Secretary
Chief Operating Officer, Chief Legal Officer, Corporate Secretary
56.23K
-5.03%

よくある質問

AN2 Therapeutics Incの上位5名の株主は誰ですか?

AN2 Therapeutics Incの上位5名の株主は以下のとおりです。Mr. Eric Easom

AN2 Therapeutics Inc(ANTX)の株式を保有している機関の数はいくつですか?

2026Q1時点で、AN2 Therapeutics Incの株式を保有している機関は104社あり、保有株式の総市場価値は約17.95Mで、全体の49.87%を占めています。2025Q4と比較して、機関の持ち株は-8864488.00増加しています。
tradingkey.logo
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。